Sironax Announces Closing of $200 Million Series B Financing
Financing from new and existing investors will support pipeline progression and expansion for age-related degenerative diseases.
Sironax, an emerging biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases, today announced the completion of a Series B financing. The round was led by Gaorong Capital and Yunfeng Capital, with participation from existing investors including Temasek, Invus, F-Prime Capital, Eight Roads, ARCH Venture Partners, K2 Venture Partners and lead investors from previous financings. In addition to the co-leads, new investors include MSA Capital, CBC Group, Long River Investments, LSV Capital, Superstring Capital, and Future Innovation Fund as well as a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA). With the closing of this round, the Company has raised over to date.
Recommended AI News: Mapp Updates its Insight-led Customer Experience Platform
[To share your insights with us, please write to firstname.lastname@example.org]